Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International.

Slides:

Advertisements

Similar presentations

1 FDA Industry Workshop Statistics in the FDA & Industry The Future David L DeMets, PhD Department of Biostatistics & Medical Informatics University of.

Advertisements

Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Amylou C. Dueck (Mayo Clinic)

NIHR Research Design Service London Enabling Better Research Forming a research team Victoria Cornelius, PhD Senior Lecturer in Medical Statistics Deputy.

Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.

DESIGN OF A DISEASE SPECIFIC MASTER PROTOCOL Jeff Allen, PhD Executive Director Friends of Cancer Research.

Statistical Issues in Incorporating and Testing Biomarkers in Phase III Clinical Trials FDA/Industry Workshop; September 29, 2006 Daniel Sargent, PhD Sumithra.

Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.

Sino-Danish Breast Cancer Research Centre Beijing Genomic Institute, Shenzhen University of Copenhagen University of Århus University of Southern Denmark.

COURSE PROPOSAL: METHODS IN CLINICAL CANCER RESEARCH Primary Instructor: Elizabeth Garrett-Mayer, PhD Professor of Biostatistics, Dept. of Public Health.

Clinical Trial Design Considerations for Therapeutic Cancer Vaccines Richard Simon, D.Sc. Chief, Biometric Research Branch, NCI

Statistical Issues in the Evaluation of Predictive Biomarkers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute

Cancer Disparities Research Partnership Program Process & Outcome Evaluation Amanda Greene, PhD, MPH, RN Paul Young, MBA, MPH Natalie Stultz, MS NOVA Research.

Oncological Sciences Center Mission: To rapidly translate research findings to the clinic by engaging clinical partners in the discovery process Vision:

Clinical Perspective. Screening/Prevention Who is at risk for what type Decision to Intervene: Risk Assessment normal Evidence of Disease Disability Death.

Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.

Career Opportunities for PharmDs in the Pharmaceutical Industry: Research & Development.

Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.

Use of Genomics in Clinical Trial Design and How to Critically Evaluate Claims for Prognostic & Predictive Biomarkers Richard Simon, D.Sc. Chief, Biometric.

CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

EN.8 - A PHASE III STUDY OF STANDARD THERAPY VERSUS RIDAFOROLIMUS IN WOMEN WITH RECURRENT OR METASTATIC ENDOMETRIAL CANCER WHO HAVE PREVIOUS HAD CHEMOTHERAPY.

ACRIN Abdominal Committee ACRIN Gynecologic Committee Fall Meeting 2010 Susanna I Lee, MD, PhD, Chair Massachusetts General Hospital.

Annual Meeting 2011 Clinical Trial Development Clinical Trial Development: OEWG, RA’s Role, and Activating Trials on Deadline Martha Heckel Protocol Associate.

NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.

ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.

Adaptive designs as enabler for personalized medicine

Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School

CTEP Protocol and Information Office (PIO) Overview.

CONFLICTS OF INTEREST ARE HERE TO STAY: PROTECTING SCIENCE FROM BIAS Susan S. Ellenberg, Ph.D. Center for Biologics Evaluation and Research, FDA Boston,

Update From FDA: Office of the Commissioner and Center for Drug Evaluation and Research Janet Woodcock, M.D. Acting Deputy Commissioner for Operations.

Measuring the Feasibility and Cost of PRO-CTCAE Implementation in Trials Presentation to NCI Stakeholders Based on work of the PRO-CTCAE Task 8 (Feasibility)

Chair:Dr. Vivien Bramwell NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP Sarcoma Committee CANADIAN SARCOMA GROUP.

Gynecologic Oncology Group Gynecologic Oncology Group (GOG) Sharon Stockman, C-CRC The University of Iowa Hospitals Iowa City, IA Chair, GOG Data Management.

SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

Cancer MetaData Standards Peter A. Covitz, Ph.D. HL7 RCRIM October 1, 2002.

Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: VEGFA and VEGFR1 and Response to Anti-VEGF Hagstrom SA, Ying G, Pauer GJT, et.

1 Statistics in Drug Development Mark Rothmann, Ph. D.* Division of Biometrics I Food and Drug Administration * The views expressed here are those of the.

BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.

Survival Analysis, Type I and Type II Error, Sample Size and Positive Predictive Value Larry Rubinstein, PhD Biometric Research Branch, NCI International.

Efficient Designs for Phase II and Phase III Trials Jim Paul CRUK Clinical Trials Unit Glasgow.

The Use of Predictive Biomarkers in Clinical Trial Design Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute

Using Predictive Classifiers in the Design of Phase III Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.

Letters of Intent (LOIs) Through the NCI’s Cancer Therapy Evaluation Program (CTEP) Dr. Patricia M. LoRusso, D.O. Karmanos Cancer Institute Wayne State.

Initiating phase 1 clinical trials in pediatric oncology National Cancer Institute Perspective Barry Anderson, MD, PhD Pediatric Section Cancer Therapy.

Introduction to Design of Genomic Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute

Enrollment and Monitoring Procedures for NCI Supported Clinical Trials Barry Anderson, MD, PhD Cancer Therapy Evaluation Program National Cancer Institute.

Robert H. Wiltrout Director, CCR Director’s Address.

Michael H. Dong MPH, DrPA, PhD  readings Epidemiology and Risk Assessment (4th of 10 Lectures on Toxicologic Epidemiology)

Role of the Drug Project Team in Formulating the Initial Development Plan of NCI-IND agents Jeff Moscow, MD IDB, CTEP.

Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.

C-1 Pegfilgrastim (Neulasta  ) Oncologic Drugs Advisory Committee Pediatric Subcommittee October 20, 2005 Amgen Inc.

CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch

CB-1 Background of Pancreatic Cancer & NCIC CTG PA.3 Study Design Malcolm Moore, MD Professor of Medicine and Pharmacology Princess Margaret Hospital Chair,

Full Proposal for the German Cancer Aid Priority Program 'Translational Oncology' (2st call) 2015 Lead Applicants: Prof. Dr. med. Magnus von Knebel Doeberitz.

Recent Studies Funded by the Progressive MS Alliance Tim Coetzee, PhD ACTRIMS 2016.

NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.

ROAD MAP: Getting a Cancer Study Done at Jefferson Meghan Wakefield,RN,CCRP Senior Director of Clinical Trials Office Clinical Research Organization.

Overview of Standard Phase II Design Issues

Martha Carvour, MD, PhD March 2, 2017

Better Science, Better Health: New Healthcare Models

Strategies for Implementing Flexible Clinical Trials Jerald S. Schindler, Dr.P.H. Cytel Pharmaceutical Research Services 2006 FDA/Industry Statistics Workshop.

Innovative Approaches to Clinical Trials

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Comments on design and sequence of biomarker studies

NRG Oncology Biospecimen Bank Report NRG Semiannual meeting

CoPrincipal Investigators

The Role of Measurable Residual Disease in AML

A New Approach to Clinical Trials

Presentation transcript:

Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International Clinical Trial Workshop ASCO, FLASCA, NCI, ONS Cordoba, Argentina September 11, 2014

Financial Disclosure  I have nothing to disclose.

Oncology Statisticians in the U.S.  There are 100 statisticians working at the NCI.  There are 5 oncology cooperative research groups in the U.S. (4 adult, 1 pediatric). Each has a statistical center with approximately 20 statisticians, most of them PhD’s.  The NCI Biometric Research Branch (NCI/BRB) has 11 PhD statisticians involved in clinical trials, including translational research, imaging and genomics, and 7 bioinformatics scientists.

Design of Cancer Clinical Trials  The cooperative group statisticians write the statistical sections, collaborating with the PI’s.  The disease oriented steering committees have monthly teleconferences to review concepts for randomized phase 2 and phase 3 trials, for which there are formal statistical reviews by NCI and extramural statisticians.  The NCI Cancer Therapy Evaluation Program (NCI/CTEP) has weekly meetings to review phase 1, phase 2, and phase 3 protocols in concept and final form.

Design and Conduct of Clinical Trials  The NCI/CTEP weekly meetings include formal reviews of all protocols by the NCI statisticians, sometimes including separate translational research and imaging reviews.  Once initiated, Data Monitoring Committees review the progress of randomized phase 2 and phase 3 trials, stopping early for futility or dramatic efficacy, assessing adequacy of accrual, and making necessary amendments, all with close collaboration between NCI and extramural clinicians and statisticians.

Design and Conduct of Clinical Trials  Each cooperative group has semi-annual meetings in which group clinicians and statisticians collaborate in the conduct of ongoing trials and the planning of new trials, with some NCI advisory collaboration.  Group statisticians do independent analyses of completed trials and collaborate with clinicians on publications, with no NCI involvement.

Clinical Trials Statistical Methodology  NCI and group statisticians have developed and published most of the major statistical methodology for the design, monitoring, and analysis of cancer clinical trials.  NCI and group statisticians have developed and published statistical methodology for incorporating biomarkers into clinical trials, including those predictive of treatment effect and those prognostic of outcome, independent of treatment, both of which are increasingly relevant to trials of molecularly targeted agents.

Bioinformatics - Statistical Genomics  Statisticians analyze the significance of gene mutations and expression in relation to patient outcome and response to particular treatments.  This involves new and special high- dimensional statistical methodology to avoid a high false discovery rate when a large number of variables are simultaneously explored.  NCI/BRB has developed and maintained, over the last 15 years, a toolkit (BRB-ArrayTools) for genomic analyses, with over 15,000 users world-wide.